Ocular Therapeutix, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Ocular Therapeutix, Inc. (Nasdaq: OCUL) develops and commercializes innovative therapies for retinal diseases and other ophthalmic conditions using its proprietary ELUTYX bioresorbable hydrogel-based delivery platform. The company markets DEXTENZA, a sustained-release intracanalicular dexamethasone insert for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older; its pipeline includes AXPAXLI (axitinib intravitreal hydrogel, also known as OTX-TKI), an investigational therapy in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), with planned expansion into non-proliferative diabetic retinopathy (NPDR) and diabetic macular edema (DME); PAXTRAVA (travoprost intracameral hydrogel), an investigational sustained-release implant for open-angle glaucoma or ocular hypertension; and other candidates leveraging ELUTYX technology for sustained delivery of anti-VEGF agents and tyrosine kinase inhibitors to address limitations of frequent eye-drop and intravitreal injection therapies. Founded in 2006 and headquartered in Bedford, Massachusetts, the company operates primarily in the United States with license and collaboration agreements, including with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA in certain regions. In 2025, Ocular Therapeutix sharpened its strategic focus exclusively on retinal diseases, rebranding as a retina-centered biopharmaceutical company; raised approximately $475 million through an underwritten public offering of 37.9 million shares priced at $12.53 each in September to fund Phase 3 trials and open-label extension studies for AXPAXLI in wet AMD and NPDR, manufacturing scale-up, and potential commercialization; and reported third-quarter financial results highlighting total cash position of $344.8 million as of September 30, excluding additional offering proceeds.
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences
Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day Transcript
Ocular Therapeutix Maps Regulatory Strategy For Lead Drug Program
Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026
Ocular Therapeutix™ to Host Investor Day on June 17, 2026
Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix, Inc. (OCUL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix, Inc. (OCUL) Q1 2026 Earnings Call Transcript
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates
Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights
Ocular Therapeutix Says FDA Talks Progressing as It Eyes AXPAXLI NDA for Wet AMD on SOL-1 Data